ReviewInflammopharmacology2025
Innovative polymer-based therapeutics targeting inflammation for responsive drug delivery in disease treatment.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With their precise, regulated release of therapeutic ingredients, polymer-based therapies provide a revolutionary approach to drug delivery. Production of nanoparticles and micelles to improve therapeutic efficacy, surface changes for targeted delivery, and structural engineering for controlled drug release are important approaches in polymer design. By limiting off-target effects and improving medication efficacy, surface modifications like PEGylation and ligand functionalisation enable designed drug delivery to organs. By shielding therapeutic chemicals from deterioration and enabling their regulated release within the body, polymeric nanoparticles and micelles enhance drug delivery even more. Polymer-based treatments are used to treat a variety of inflammatory diseases, such as cancer, heart disease, rheumatoid arthritis, and neurological conditions. These technologies allow for site-specific medication release by making use of the distinct biochemical characteristics of sick or inflammatory tissues, such as localised acidity or elevated ROS levels. Polymer-based solutions could transform treatment outcomes by decreasing systemic side effects and focussing on localised inflammation. To further improve patient care, future research will concentrate on enhancing these systems' specificity, effectiveness, and clinical translation.
Indexed as
Identifiers
41083766What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.